Navigation Links
NexGenix Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:11/1/2007

NEW YORK, Nov. 1 /PRNewswire/ -- NexGenix Pharmaceuticals, a privately held biotechnology company focused on developing drugs to treat the orphan- designated tumor suppressor disorder neurofibromatosis and related sporadic tumors, today announced that Allan E. Rubenstein, MD, Chief Executive Officer of NexGenix will be presenting at the Acumen BioFin and Rodman & Renshaw 9th Annual Healthcare Conference at 3:00 pm on November 5th, 2007 at the New York Palace Hotel. Dr. Rubenstein will be providing an overview of NexGenix and discussing recent company highlights.

The Acumen BioFin and Rodman & Renshaw 9th Annual Healthcare Conference will include presentations by over 350 companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders.

About NexGenix Pharmaceuticals

NexGenix Pharmaceuticals is a US-based biotechnology company focused on drug development for Neurofibromatosis Types 1 and 2 and related sporadic tumors. Neurofibromatosis, or NF, is a genetic disorder characterized by the development of tumors along nerves. NexGenix has assembled a team of top NF clinicians and researchers on its Scientific Advisory Board and has developed a proprietary screening platform for both Neurofibromatosis Type 1 and 2. NexGenix will soon seek an IND for a unique treatment for NF1.

For more information, please visit the NexGenix website at http://www.nexgenixpharm.com. The information on our website does not, however, form a part of this press release.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements.


'/>"/>
SOURCE NexGenix Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... & Scientific Session on September 16-17 in Greenville, SC at the Bon Secours ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... Las Vegas ... revamped South Rancho location on Friday, March 10, 2017, 4-7 pm PST. For more ... but this clinic, located in the South Rancho neighborhood, has been renovated to provide ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... BrightStar Care ... of Choice Awards from Home Care Pulse. This award is granted only to top-ranking ... BrightStar Care Marietta is now ranked among home care providers from across the ...
(Date:2/27/2017)... ... 2017 , ... Bo Chen, PhD is the recipient of the 2017 ASLMS ... the Plenary Session at ASLMS 2017, the Annual Conference of the American Society for ... 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen will ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Robert E. Burke, ... medical group. But his impoverished upbringing and life experiences could have led him down ... Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... and Markets has announced the addition of the "Active Pharmaceutical ... The global active pharmaceutical ingredients (API) market is ... The rising prevalence of lifestyle-induced & age-related diseases and cancer is ... recombinant molecular technologies and high capitalization for development of novel drugs ...
(Date:2/28/2017)... SINGAPORE and SAN FRANCISCO , February 27, 2017 ... four Se D ... portfolio of biotechnology assets   LOI contemplates capital ... term growth plan for building shareholder value   Amarantus names ... interim-CFO of Amarantus   SeD Biomedical Inc. ...
(Date:2/28/2017)... February 28, 2017 The global  pulse oximeters market  is ... by Grand View Research, Inc. The pulse oximeters market is anticipated to witness ... prevalence of target diseases such as chronic obstructive pulmonary disease (COPD), sleep apnea, ... ... Grand View Research Logo ...
Breaking Medicine Technology: